NCT06538974 Adherence to Long-term Exoskeleton Rehabilitation to Treat Lower Limb Weakness and / or Deficiencies in Adult Population
| NCT ID | NCT06538974 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Wandercraft |
| Condition | Motor Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2023-02-16 |
| Primary Completion | 2027-07-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2023-02-16 with a primary completion date of 2027-07-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In 2019, approximately 2.4 billion people worldwide required rehabilitation for various health pathologies, a 63% increase since 1990. It has been suggested that current rehabilitation frameworks (inpatient, outpatient, and community-based) are insufficient to meet local population needs due to issues like long waiting times, lack of facilities, prioritization, funding, and accessibility.Patients with lower limb weaknesses, resulting from various conditions (for example stroke, traumatic brain injury, spinal cord injury and others) require long-term management and motivation for engagement, which are crucial for functional outcomes. This highlights the need for sustainable gait and balance rehabilitation. New technologies like exoskeletons have shown promising results in short-term inpatient programs, improving gait, balance, and quality of life, however, long-term follow-up data are still needed. The present clinical investigation is a national, prospective, open-label interventional trial, proposing a 12-month outpatient rehabilitation program with the Atalante X exoskeleton to treat lower limb weakness and/or impairments in 100 participants. The rehabilitation program consists of at least one exoskeleton rehabilitation session per week. At the end of the first-year experimental phase, participants can continue for an additional year in the voluntary phase. The program aims to explore the potential long-term effects of supervised robotic rehabilitation on motor, cognitive, bowel, bladder functions, quality of life, and well-being. Assessments are conducted at baseline, after 4 and 12 months of exoskeleton rehabilitation, and at 16 and 24 months for participants in the voluntary phase.
Eligibility Criteria
Inclusion Criteria: * Patient suffering from lower limb weaknesses and / or deficiencies regardless of the cause * Adult patient ≥18 years old * Patient able to read and write in French and who have signed an informed consent form * Patient affiliated to a social security system. Exclusion Criteria: * Individual with severe spasticity of adductor muscles, hamstring, quadriceps and triceps surae. Severe spasticity is defined by a score of 4 on the modified Ashworth scale * Pregnant woman * Individual with history of osteoporotic fracture and / or pathology or treatment causing secondary osteoporosis * Pressure Ulcer of Grade I or higher according to the NPUAP International Pressure Ulcer Classification System- EPUAP, in areas of contact with the Atalante X system * Severe aphasia limiting ability to express needs or to fulfil questionnaires, at the discretion of the physician. * Patient with a cardiac or respiratory contraindication to physical exertion, at discretion of the physician * Patient unable to deliver his/her consent * Patient under legal protection * Patient participating at the same time in another study * Patients with morphological contraindications to the use of the Atalante X exoskeleton (as per user's manual) with exceptions as follows: knee flessum of 20° authorized if sensibility is present; equinus of the ankle of 20° allowed regardless of presence or absence of sensibility, hip flessum of 20° allowed regardless of presence or absence of sensibility.
Contact & Investigator
Rebecca Sauvagnac, MD
PRINCIPAL INVESTIGATOR
Wandercraft
Frequently Asked Questions
Who can join the NCT06538974 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Motor Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06538974 currently recruiting?
Yes, NCT06538974 is actively recruiting participants. Contact the research team at rebecca.sauvagnac@wandercraft.health for enrollment information.
Where is the NCT06538974 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT06538974 clinical trial?
NCT06538974 is sponsored by Wandercraft. The principal investigator is Rebecca Sauvagnac, MD at Wandercraft. The trial plans to enroll 100 participants.